Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 4, 2013, Pages 357-361

  Schweizer, M T ^a   Lin, J ^b   Blackford, A ^a   Bardia, A ^c   King, S ^a   Armstrong, A J ^d   Rudek, M A ^a   Yegnasubramanian, S ^a   Carducci, M A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Demethylation; Disulfiram; Epigenetics; Hypomethylation

Indexed keywords

DISULFIRAM; PROSTATE SPECIFIC ANTIGEN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; ATAXIA; CANCER FATIGUE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIPLOPIA; DISEASE ASSOCIATION; DIZZINESS; DNA CONTENT; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HEARING IMPAIRMENT; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEUROPATHY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RECURRENT CANCER; SYNDROME DELINEATION;

AGED; ANTINEOPLASTIC AGENTS; CERULOPLASMIN; DISULFIRAM; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84887615265     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.28     Document Type: Article

References (28)

1. Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009; 150: 3991-4002.
2. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64: 1975-1986.
3. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008; 68: 8954-8967.
4. Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 2013; 5: 169ra10.
5. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209-213.
6. Mack GS. Epigenetic cancer therapy makes headway. J Natl Cancer Inst 2006; 98: 1443-1444.
7. Muller CI, Ruter B, Koeffler HP, Lubbert M. DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. Curr Pharm Biotechnol 2006; 7: 315-321.
8. Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate 2011; 71: 333-343.
9. Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V et al. High-throughput cellbased screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 2009; 15: 6070-6078.
10. Jeltsch A. Beyond Watson and Crick: DNA methylation and molecular enzymology of DNA methyltransferases. Chembiochem 2002; 3: 274-293.
11. Marikovsky M, Nevo N, Vadai E, Harris-Cerruti C. Cu/Zn superoxide dismutase plays a role in angiogenesis. Int J Cancer 2002; 97: 34-41.
12. Shian SG, Kao YR, Wu FY, Wu CW. Inhibition of invasion and angiogenesis by zincchelating agent disulfiram. Mol Pharmacol 2003; 64: 1076-1084.
13. Yakisich JS, Siden A, Eneroth P, Cruz M. Disulfiram is a potent in vitro inhibitor of DNA topoisomerases. Biochem Biophys Res Commun 2001; 289: 586-590.
14. Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003; 104: 504-511.
15. Liu GY, Frank N, Bartsch H, Lin JK. Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFkappaB, c-fos/c-jun, and p53 proteins. Mol Carcinog 1998; 22: 235-246.
16. Kim CH, Kim JH, Moon SJ, Hsu CY, Seo JT, Ahn YS. Biphasic effects of dithiocarbamates on the activity of nuclear factor-kappaB. Eur J Pharmacol 2000; 392: 133-136.
17. Cho HJ, Lee TS, Park JB, Park KK, Choe JY, Sin DI et al. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 2007; 40: 1069-1076.
18. Cen D, Gonzalez RI, Buckmeier JA, Kahlon RS, Tohidian NB, Meyskens Jr. FL. Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther 2002; 1: 197-204.
19. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 2005; 7: R897-R908.
20. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006; 66: 10425-10433.
21. Chen D, Peng F, Cui QC, Daniel KG, Orlu S, Liu J et al. Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosci 2005; 10: 2932-2939.
22. Lovborg H, Oberg F, Rickardson L, Gullbo J, Nygren P, Larsson R. Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Int J Cancer 2006; 118: 1577-1580.
23. Huang WY, Su LJ, Hayes RB, Moore LE, Katki HA, Berndt SI et al. Prospective study of genomic hypomethylation of leukocyte DNA and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2012; 21: 2014-2021.
24. Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 1992; 369: 15-26.
25. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22: 537-556.
26. Bjornsson HT, Sigurdsson MI, Fallin MD, Irizarry RA, Aspelund T, Cui H et al. Intraindividual change over time in DNA methylation with familial clustering. JAMA 2008; 299: 2877-2883.
27. Henry NL, Dunn R, Merjaver S, Pan Q, Pienta KJ, Brewer G et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 2006; 71: 168-175.
28. Lin J, Beer TM, Ryan CJ, Mathew P, Wilding G, Morris M et al. A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial. J Clin Oncol 2009; 27: 15s.